A role for nucleolin in functional improvement in stroke.

Samuel P Bridges, Mary Hovanesyan, Srbui Azarapetian, Ofri Abraham, Ida Rishal, Mike Fainzilber, S Thomas Carmichael

Abstract read

In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel P BridgesDepartment of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.

Mary HovanesyanDepartment of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.

Srbui AzarapetianDepartment of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.

Ofri AbrahamDepartments of Biomolecular Sciences and Molecular Neuroscience, Weizmann Institute of Science, Rehovot 7610001, Israel.

Ida RishalDepartments of Biomolecular Sciences and Molecular Neuroscience, Weizmann Institute of Science, Rehovot 7610001, Israel.

Mike FainzilberDepartments of Biomolecular Sciences and Molecular Neuroscience, Weizmann Institute of Science, Rehovot 7610001, Israel.

S Thomas CarmichaelDepartment of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke remains a global health concern and a leading cause of adult-onset disability due to limited intrinsic repair capability. Here, we identify nucleolin as a targetable regulator of the repair programs activated following ischemic injury. Through neuron-specific subcellular targeting of axonal nucleolin in the post-stroke recovery period, we see enhanced axonal sprouting and accelerated functional recovery following motor cortex stroke. These findings demonstrate that interference in localized nucleolin functions following cortical stroke is a viable strategy to enhance functional recovery.

Indexed as

cell biologymolecular biologyneuroscience

Identifiers

PMID42291226

DOI10.1016/j.isci.2026.116134

PMCPMC13253107

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.